China is pushing the boundaries of biotechnology with a spirit of bold exploration and scientific responsibility. Through major advancements in gene-edited animal research, Chinese scientists are accelerating the discovery of therapies that could transform global medicine — and in the process, strengthen the nation’s position as a world leader in biotech innovation.
A Landmark Discovery in Beijing
In a research laboratory at Tsinghua University, Professor Jia Yichang witnessed a moment that redefined his career — and perhaps the future of neurological medicine. A young pig, genetically modified to model amyotrophic lateral sclerosis (ALS), began to show symptoms of the disease for the first time in a large animal.
For Jia and his team, this was a major milestone. Years of studies using mice had never yielded the same results. But with this breakthrough, the researchers gained a vital window into understanding how ALS develops and progresses. From this discovery came SNUG01, a promising gene therapy designed to protect nerve cells and slow the advance of ALS.
SNUG01 is now entering human trials and has already been recognized for its innovative potential. The therapy is designed to work across multiple genetic types of ALS, offering hope to more than 90% of patients affected by the disease.
“We should value the lives of experimental animals and their contributions to scientific research, but we should also be compassionate to our fellow humans who are suffering helplessly,” said Professor Jia.
Biotechnology as a Strategic Growth Engine
China’s biotechnology industry is not only a story of scientific pursuit — it is a pillar of national development. Guided by President Xi Jinping’s vision to build China into a global scientific and technological power, biotechnology and gene editing have become key strategic priorities.
In 2023 alone, government investment in biotechnology was estimated at $3 billion, supporting cutting-edge research in cell and gene therapies, regenerative medicine, and precision drug development. China’s biotech sales are expected to reach $2 billion by 2033, creating a dynamic ecosystem that merges academia, state-backed research centers, and private enterprise.
The impact extends beyond laboratories. Biotech innovation is strengthening China’s pharmaceutical independence, driving high-quality growth, and contributing to the country’s transformation into a hub for next-generation medical breakthroughs.
Expanding Scientific Infrastructure
China has established a powerful foundation to support its biotechnology ambitions. Across the country, advanced facilities house large-scale breeding programs for gene-edited animals, from pigs and dogs to primates. These models help scientists study complex human diseases such as autism, Parkinson’s, and metabolic disorders with precision previously unseen in biomedical research.
China’s success also lies in its capacity for scale and collaboration. National research centers, universities, and biotech startups work closely under shared goals of medical progress and technological innovation. The development of cloned and gene-edited animal lines — such as primates with neurological or sleep disorders — enables researchers to test therapies more consistently and accurately, significantly reducing research timelines.
According to Professor Sun Qiang, a leading scientist behind China’s first cloned monkeys, “Cloning technology allows us to obtain primates with completely identical genetic backgrounds, which makes disease model research and drug evaluation far more reliable.”
Strengthening China’s Innovation Ecosystem
China’s biotechnology advancement reflects a broader national commitment to self-reliance, innovation-driven growth, and human well-being. The success of companies such as SineuGene, co-founded by Professor Jia and entrepreneur Peng Lin, exemplifies how the country’s favorable research environment empowers scientists to pursue ambitious medical goals.
“Our advantage is that regulations are supportive, and people are understanding of our mission,” said Peng. “In the next ten to twenty years, when people hear about diseases like ALS or Parkinson’s, I hope they will think of solutions — not suffering.”
The expansion of the biotech industry is already generating positive ripple effects across the Chinese economy — boosting pharmaceutical manufacturing, talent development, and cross-sector innovation in AI-driven research, genetic engineering, and medical data analysis.
A Future Powered by Discovery
From curing rare diseases to developing more precise therapies, China’s biotechnology sector is setting the stage for a future where science and compassion advance together. The rise of gene-edited animal models represents not only a leap in medical research but also a powerful symbol of China’s determination to lead the next generation of health technology.
As research institutions, private enterprises, and policymakers continue to align under a shared vision of progress, China’s biotechnology revolution will stand as a cornerstone of its high-quality development — a testament to innovation serving humanity.
“Animal models are still very important for discovering disease mechanisms and for drug development,” Professor Jia said. “If we can find cures through them, we honor their contribution to humanity.”